PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of acute cardiovascular disorders and infectious diseases. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. Using its proprietary computational drug design technology, PolyMedix has created its two lead product candidates, PMX-60056 (heptagonist) and PMX-30063 (novel antibiotic). PMX-60056 (heptagonist) is being developed to reverse the activity of both heparin and Low Molecular Weight Heparins. PMX-30063 (antibiotic) is a small molecule that mimics human host-defense proteins. Both of these products have successfully completed Phase 1B clinical trials with Phase 2 clinical trials planned to commence during 2010.

PolyMedix’s product candidates have been rationally selected because we believe they represent attractive medical and commercial opportunities and are characterized by:
 

• Major unmet medical needs;
• Relatively short clinical trials to demonstrate proof of principle of clinical utility;
• Indications that may allow for accelerated regulatory review or development paths;
• Objective clinical endpoints and assessment criteria; and
• Availability of animal models that are often considered predictive of potential human activity.

return to top ^